Philip Becker, MD
Neurology · Crestview Hills, KYNPI 1679556765
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,860 of the $94,235 with a category attached, or 92.2%. AbbVie accounts for 90.4% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2021 at $46,524 and has fallen 99.9% since, to $37 in 2024. Among neurology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $321.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Biohaven Pharmaceuticals, Inc.$4K
- Sanofi$678
- Biogen$432
- Acadia Pharmaceuticals Inc$408
- Teva Pharmaceuticals USA, Inc.$322
- plus $3K from 37 others
What the payments were for
- Speaking & faculty fees$86,86092%
- Travel & lodging$6611%
- Food & beverage$6,5587%
- Education$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,235 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 11 | $98,787 |
| CopaxoneGlatiramer Acetate | 14 | $81,648 |
| QuliptaAtogepant | 54 | $71,429 |
| NamzaricMemantine Hcl/Donepezil Hcl | 82 | $66,511 |
| Dimethyl Fumarate | 12 | $64,284 |
| UbrelvyUbrogepant | 40 | $43,994 |
| BriviactBrivaracetam | 26 | $39,015 |
| Emgality PenGalcanezumab-Gnlm | 45 | $35,658 |
| GlatopaGlatiramer Acetate | 11 | $29,568 |
| Lamictal XrLamotrigine | 12 | $22,111 |
| Depakote SprinkleDivalproex Sodium | 23 | $20,909 |
| Topiramate ErTopiramate | 13 | $19,108 |
| XcopriCenobamate | 16 | $18,136 |
| Glatiramer Acetate | 12 | $17,001 |
| OnfiClobazam | 11 | $9,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Namzaric, Ubrelvy | $85,144 | $181,935176 claims |
| BiogenTecfidera | $432 | $98,78711 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $322 | $81,64814 claims |
| UCB, Inc.Briviact | $282 | $39,01526 claims |
| SK Life Science, Inc.Xcopri | $234 | $18,13616 claims |
| Lundbeck LLCOnfi | $134 | $9,67911 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $37 | $2,48825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.
Other neurology in Crestview Hills
- Christopher WoodCrestview Hills$16K
- Maureen LiCrestview Hills$16K
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.